van Helden, E. J.
Vacher, Y. J. L.
van Wieringen, W. N.
van Velden, F. H. P.
Verheul, H. M. W.
Hoekstra, O. S.
Boellaard, R.
Menke-van der Houven van Oordt, C. W. http://orcid.org/0000-0002-5404-5883
Funding for this research was provided by:
KWF - Alpe d'Huez (2012-5565)
Article History
Received: 4 April 2018
Accepted: 17 July 2018
First Online: 9 August 2018
Compliance with ethical standards
: This work was supported by KWF - Alpe d’Huez [2012–5565]. The funders had no role in study design, data collection and analysis or preparation of the manuscript.
: Henk Verheul is member of the advisory board of Erbitux (Merck); he has also received honoraria from Boehringer Ingelheim and Roche for his consultancy work. Henk Verheul received research funding from Amgen, Vitromics Healthcare, Immunovo BV, Roche and Novartis. There are no conflicts of interests for all others.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.